lorundrostat Dose 2

DRUG2 trials

Sponsors

Mineralys Therapeutics Inc.

Conditions

Hypertension

Phase 2

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

CompletedNCT05769608

Mineralys Therapeutics Inc.Hypertension

Start: 2023-03-13End: 2025-01-15Updated: 2026-01-20

Phase 3

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

CompletedNCT06153693

Mineralys Therapeutics Inc.Hypertension

Start: 2023-11-22End: 2025-01-24Updated: 2026-05-01

Related Papers

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension

JAMA2025-06-3026 citations

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

New England Journal of Medicine2025-04-2352 citations